These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28569041)

  • 21. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
    Schirripa M; Zhang W; Heinemann V; Cao S; Okazaki S; Yang D; Loupakis F; Berger MD; Ning Y; Miyamoto Y; Suenaga M; Gopez RF; West JD; Hanna D; Barzi A; Falcone A; Stintzing S; Lenz HJ
    Int J Cancer; 2017 Jul; 141(2):383-392. PubMed ID: 28369940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
    Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
    Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
    Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
    Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
    Iwamoto S; Hazama S; Kato T; Miyake Y; Fukunaga M; Matsuda C; Bando H; Sakamoto J; Oba K; Mishima H
    Anticancer Res; 2014 Apr; 34(4):1967-73. PubMed ID: 24692733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Artaç M; Coşkun HŞ; Dane F; Karabulut B; Korkmaz L; Karaağaç M; Çabuk D; Karabulut S; Faruk Aykan N; Doruk H; Avcı N; Turhal NS
    J Gastrointest Cancer; 2016 Sep; 47(3):264-72. PubMed ID: 27126591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
    Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
    Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerling R; Kirchner T; Jung A; Folwaczny M; Yang D; Ning Y; Sebio A; Stremitzer S; Sunakawa Y; Matsusaka S; Yamauchi S; Loupakis F; Cremolini C; Falcone A; Lenz HJ
    Mol Cancer Ther; 2015 Oct; 14(10):2374-81. PubMed ID: 26206335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
    Yamaguchi K; Ando M; Ooki A; Beier F; Guenther S; von Hohnhorst P; Van Cutsem E
    Clin Colorectal Cancer; 2017 Jun; 16(2):e29-e37. PubMed ID: 28081962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
    Holch JW; Held S; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; von Einem JC; Michl M; Heinemann V
    Ann Oncol; 2020 Jan; 31(1):72-78. PubMed ID: 31912799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
    Pfeiffer P; Sorbye H; Qvortrup C; Karlberg M; Kersten C; Vistisen K; Lindh B; Bjerregaard JK; Glimelius B
    Clin Colorectal Cancer; 2015 Sep; 14(3):170-6. PubMed ID: 25956187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
    Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
    Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
    Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
    Feng Q; Wei Y; Ren L; Zheng P; Yu Y; Ye Q; Ding J; Chen J; Chang W; Zhong Y; Zhu D; Lin Q; Yang L; Qin X; Xu J
    Oncotarget; 2016 Mar; 7(10):11380-96. PubMed ID: 26863631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.
    Sunakawa Y; Stintzing S; Cao S; Heinemann V; Cremolini C; Falcone A; Yang D; Zhang W; Ning Y; Stremitzer S; Matsusaka S; Yamauchi S; Parekh A; Okazaki S; Berger MD; Graver S; Mendez A; Scherer SJ; Loupakis F; Lenz HJ
    Ann Oncol; 2015 Dec; 26(12):2450-6. PubMed ID: 26416897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.